Hit enter to search or ESC to close
Cortexyme
  • Home
  • Team
  • Pipeline
  • Science
  • News
  • Investors
  • Careers
Cortexyme
All Posts By

Rico Severa

News

Cortexyme Appoints Dr. Philip Low to its Board of Directors

By Rico Severa | News
News

Cortexyme Successfully Completes Acquisition of Novosteo

By Rico Severa | News
News

Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

By Rico Severa | News
News

Cortexyme Announces Agreement to Acquire Novosteo

By Rico Severa | News
News

Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population

By Rico Severa | News
News

Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors

By Rico Severa | News
News

Cortexyme to Present New GAIN Trial Data at AD/PD 2022

By Rico Severa | News
News

Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders

By Rico Severa | News
News

Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588

By Rico Severa | News
EventsNews

Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th

By Rico Severa | Events, News
1 2 Next

Please note our Privacy Policy and Terms of Use. ©2022 Cortexyme

  • Home
  • Team
  • Pipeline
  • Science
  • News
  • Investors
  • Careers